European Journal of Cancer
Volume 42, Issue 15 , Pages 2472-2479 , October 2006

To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound

  • Michele Lamuraglia

      Affiliations

    • Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • Section of Internal Medicine, Department of Internal Medicine and Public Medicine, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
    • ,
  • Bernard Escudier

      Affiliations

    • Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Linda Chami

      Affiliations

    • Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Brian Schwartz

      Affiliations

    • Bayer Pharmaceuticals Corporation, West Haven CT 06516, USA
    • ,
  • Jérome Leclère

      Affiliations

    • Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Alain Roche

      Affiliations

    • Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Nathalie Lassau

      Affiliations

    • Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • Corresponding Author InformationCorresponding author: Tel.: +33 1 42 11 60 14; fax: +33 1 42 11 60 29.

Received 15 February 2006 ,Revised 18 April 2006 ,Accepted 20 April 2006.

References 

  1. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des. 2002;8:2255–2257
  2. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109
  3. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4:677–685
  4. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21days on/7days off in patients with advanced, refractory solid tumours. Br J Cancer. 2005;
  5. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965–972
  6. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10:6388S–6392S
  7. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296:2404–2407
  8. Lassau N, Lamuraglia M, Leclere J, Rouffiac V. Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents. J Radiol. 2004;85:704–712
  9. Lassau N, Lamuraglia M, Vanel D, et al. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49cases. Ann Oncol. 2005;16:1054–1060
  10. Lassau N, Paturel-Asselin C, Guinebretiere JM, et al. New hemodynamic approach to angiogenesis: color and pulsed Doppler ultrasonography. Invest Radiol. 1999;34:194–198
  11. Niermann KJ, Fleischer AC, Donnelly EF, et al. Sonographic depiction of changes of tumor vascularity in response to various therapies. Ultrasound Q. 2005;21:61–67
  12. Lassau N, Spatz A, Avril MF, et al. Value of high-frequency US for preoperative assessment of skin tumors. Radiographics. 1997;17:1559–1565
  13. Lassau N, Mercier S, Koscielny S, et al. Prognostic value of high-frequency sonography and color Doppler sonography for the preoperative assessment of melanomas. AJR Am J Roentgenol. 1999;172:457–461
  14. Lassau N, Koscielny S, Opolon P, et al. Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo. Invest Radiol. 2001;36:50–55
  15. Lassau N, Koscielny S, Avril MF, et al. Prognostic value of angiogenesis evaluated with high-frequency and color Doppler sonography for preoperative assessment of melanomas. AJR Am J Roentgenol. 2002;178:1547–1551
  16. Henri P, Tranquart F. B-flow ultrasonographic imaging of circulating blood. J Radiol. 2000;81:465–467
  17. WHO Handbook for reporting results of cancer treatment. World Health Organisation Offset Publication. (48). 1979. Geneva (Switzerland).
  18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  19. Lawrence H, Schwartz B. Centional and novel techniques for therapeutic. Radio Soc Nord Am (RSNA) 90th Science Assembley and Annual Meeting, 115. 2004 [Personal communication].
  20. Eggermont AM. Evolving imaging technology: contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response. Ann Oncol. 2005;16:995–996
  21. Hochedez P, Lassau N, Bonvalot S, et al. Treatment of local recurrent melanomas by isolated limb perfusion: value of Doppler ultrasonography. J Radiol. 2003;84:597–603
  22. Lassau N, Chawi I, Rouffiac V, et al. Interest of color Doppler ultrasonography to evaluate a new anti-angiogenic treatment with thalidomide in metastatic renal cell carcinoma. Bull Cancer. 2004;91:629–635
  23. Bauer A, Solbiati L, Weissman N. Ultrasound imaging with SonoVue: low mechanical index real-time imaging. Acad Radiol. 2002;9(Suppl 2):S282–S284
  24. Rouffiac V, Bouquet C, Lassau N, et al. Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol. 2004;39:350–356
  25. Bartolozzi C, Lencioni R, Ricci P, et al. Hepatocellular carcinoma treatment with percutaneous ethanol injection: evaluation with contrast-enhanced color Doppler US. Radiology. 1998;209:387–393
  26. Hsu C, Chen CN, Chen LT, et al. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors. Radiology. 2005;235:509–516
  27. Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol. 2002;13:1029–1035
  28. Kabakci N, Igci E, Secil M, et al. Echo contrast-enhanced power Doppler ultrasonography for assessment of angiogenesis in renal cell carcinoma. J Ultrasound Med. 2005;24:747–753
  29. Schwartz LH, Mazumdar M, Wang L, et al. Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. Cancer. 2003;98:1611–1619
  30. Fukata S, Inoue K, Kamada M, et al. Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer. 2005;103:931–942
  31. Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol. 2005;16:7–15
  32. Dancey JE. Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap?. J Clin Oncol. 2004;22:2975–2977
  33. Ratain MJ, Flaherty KT, Stadler WM, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). Am Soc Clin Oncol. 2004;23:381;[Abstract]
  34. Escudier B, Szczylik T, Stadler WM, et al. Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Am Soc Clin Oncol. 2004;23:280s;[Abstract]
  35. Lassau N, Lamuraglia M, Chami L, et al. Doppler-Ultrasonography with perfusion software and contrast medium injection as a tool for early evaluation of gastro intestinal stromal tumor (GIST) treated by imatinib. Am Soc Clin Oncol. 2005;23:206s;[Abstract]

☆ This work was presented at the ASCO and ECCO meetings in 2005.

PII: S0959-8049(06)00607-1

doi: 10.1016/j.ejca.2006.04.023

European Journal of Cancer
Volume 42, Issue 15 , Pages 2472-2479 , October 2006

Article Tools

* Image Usage & Resolution